KCL-286 (C286) is a potent, selective and orally bioavailable RARβ agonist with EC50 of 1.9 nM/26 nM/13 nM for RARβ/RARα/RARγ, respectively.
KCL-286 (C286) displays 5-23 fold selectivity for RARβ over RARα (23 fold) and for RARβ over RARγ (5 fold) against the human RAR ligand-binding domains.
KCL-286 (C286) possess a promising pharmacokinetic profile in both rat and dog.
KCL-286 (C286) increases neurite outgrowth in vitro and induce sensory axon regrowth in vivo in a rodent model of avulsion and crush injury.
